Skip to main
PRVA

PRVA Stock Forecast & Price Target

PRVA Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 25%
Buy 67%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

Privia Health Gr is well-positioned for long-term success due to their effective support of primary care physicians and their strong financial performance. The company's focus on value-based care and their solid partnerships with medical groups, health plans, and health systems have contributed to their record profitability and potential for future growth. With their strong leadership and strategic acquisitions, PRVA is expected to continue delivering strong financial results and leading the way in physician enablement services.

Bears say

Privia Health Gr is a physician enablement company with a strong presence in over 24 states. While the company's technology and service solutions are impressive, its agnostic approach and lack of visibility into the size and traction of its FFS and VBC books may hinder its short-term profitability. Additionally, the company's reliance on individual physicians for growth in existing markets and its asset-light model present risks. However, with the growing shift towards value-based care in the healthcare market, Privia's experienced management team and broad expertise position it well for future success.

PRVA has been analyzed by 12 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 67% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Privia Health Group and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Privia Health Group (PRVA) Forecast

Analysts have given PRVA a Buy based on their latest research and market trends.

According to 12 analysts, PRVA has a Buy consensus rating as of Apr 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.08, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.08, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Privia Health Group (PRVA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.